<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377036</url>
  </required_header>
  <id_info>
    <org_study_id>UKM14_0016</org_study_id>
    <secondary_id>HE1646/5-1 and HE1646/5-2</secondary_id>
    <nct_id>NCT03377036</nct_id>
  </id_info>
  <brief_title>Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography</brief_title>
  <acronym>TOSYMA</acronym>
  <official_title>Prospective Randomized Comparison of Digital Breast Tomosynthesis Plus Synthesized Images Versus Standard Full-field Digital Mammography in Population-based Screening (TOSYMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, multicenter, multivendor, controlled, diagnostic superiority&#xD;
      trial to compare digital breast tomosynthesis plus synthesized 2D mammograms (DBT+s2D) versus&#xD;
      standard 2D full-field digital mammography (2D-FFDM) regarding the effectiveness as screening&#xD;
      modality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate whether digital breast tomosynthesis plus&#xD;
      synthesized 2D mammograms leads to a relevant increase in the detection rate of&#xD;
      screening-detected invasive cancers compared to 2D full-field digital mammography in routine&#xD;
      screening according to the European Guidelines. Furthermore, the incidence rate of interval&#xD;
      cancers within a 24 months interval after screening will be compared between both study arms&#xD;
      in order to investigate the potential for overdiagnosis.&#xD;
&#xD;
      According to the pre-defined order of both primary endpoints and the primary objective of the&#xD;
      study in the planning phase, the initial sample size calculation was based solely on the&#xD;
      first primary endpoint (invasive breast cancer detection rate). Given the increasing national&#xD;
      and international attention of interval cancers to assess the impact of potential&#xD;
      overdiagnosis caused by tomosynthesis, we have planned a sample size increase from 80,000 to&#xD;
      120,000 study participants to achieve a reasonable statistical power for the evaluation of&#xD;
      both primary endpoints. The revised sample size calculation was carried out without knowledge&#xD;
      of the data from the currently recruiting TOSYMA study, i.e. all planning assumptions were&#xD;
      based on external data that do not belong to the ongoing study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to either Digital Breast Tomosynthesis plus synthesized 2D mammograms (DBT+s2D) or 2D Full-Field Digital Mammography (2D-FFDM)</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of invasive breast cancers</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected invasive breast cancer divided by the number of all women screened. A screening-detected breast cancer is classified as invasive carcinoma if the pT category (pathological tumor size) of the TNM classification falls into one of the following categories: pT1mic, pT1a, pT1b, pT1c, pT1, pT2, pT3, pT4a, pT4b, pT4c, pT4d, pT4, pTX (for evaluation purpose pTX defines histologically approved invasive breast cancer with missing tumor diameter) or the final pathological categorization has been done after neoadjuvant therapy (ypT), implying an invasive cancer prior to therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative 24 months incidence of interval cancers</measure>
    <time_frame>24 months after routine screening visit</time_frame>
    <description>The 24 months incidence of interval cancers is defined as the number of women that develop a ductal carcinoma in situ or an invasive breast cancer in the 24 months interval after a negative screening examination divided by the number of all women with a negative screening result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rate of ductal carcinoma in situ (DCIS)</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected ductal carcinoma in situ (if the pT category of the TNM classification falls into the category pTis) divided by the number of all women screened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rate of tumor category pT1</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected invasive breast cancers of the category pT1 divided by the number of all women screened. A screening-detected breast cancer is classified as breast cancer of tumor category pT1 if tumor size is â‰¤ 20 mm in greatest dimension and the respective pT subcategory of the pTNM classification is one of the following: pT1mic, pT1a, pT1b, pT1c, pT1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall rate for further assessment</measure>
    <time_frame>Routine Screening Visit</time_frame>
    <description>Number of women with recalls for further assessment divided by the number of all women screened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of recall for further assessment (PPV1)</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected malignancies (ductal carcinoma in situ or invasive breast cancer) divided by the number of women with recalls for further assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative 12 months incidence of interval cancers</measure>
    <time_frame>12 months after routine screening visit</time_frame>
    <description>The 12 months incidence of interval cancers is defined as the number of women that develop a ductal carcinoma in situ or an invasive breast cancer in the 12 months interval after a negative screening examination divided by the number of all women with a negative screening result.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99689</enrollment>
  <condition>Breast Cancer Screening</condition>
  <arm_group>
    <arm_group_label>DBT+s2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digital breast tomosynthesis plus synthesized 2D mammograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D-FFDM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2D full-field digital mammography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DBT+s2D</intervention_name>
    <description>Digital breast tomosynthesis plus synthesized 2D mammograms</description>
    <arm_group_label>DBT+s2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2D-FFDM</intervention_name>
    <description>2D full-field digital mammography</description>
    <arm_group_label>2D-FFDM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women eligible to participate in the National Mammography Screening Program of Germany&#xD;
&#xD;
          -  Informed decision for mammography screening&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  No prior participation in the TOSYMA trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast cancer up to 5 years prior to study invitation&#xD;
&#xD;
          -  Previous mammography examination &lt; 12 months,&#xD;
&#xD;
          -  Breast implants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Heindel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic for Radiology, University of Muenster / University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Screening-Einheit Hannover; Mammographie-Einheit Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Nordost; Mammographie-Einheit LÃ¼neburg</name>
      <address>
        <city>LÃ¼neburg</city>
        <state>Niedersachsen</state>
        <zip>21337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Nord; Mammographie-Einheit Stade</name>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Mitte; Mammographie-Einheit Vechta</name>
      <address>
        <city>Vechta</city>
        <state>Niedersachsen</state>
        <zip>49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Nordwest; Mammographie-Einheit Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <state>Niedersachsen</state>
        <zip>26382</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Aachen-DÃ¼ren-Heinsberg; Mammographie-Einheit Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Referenz-Screening-Einheit MÃ¼nster-Nord/Warendorf; Mammographie-Einheit Ahlen</name>
      <address>
        <city>Ahlen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit KÃ¶ln rechtsrheinisch, Leverkusen, Rhein.-Berg. Kreis, Oberbergischer Kreis; Mammographie-Einheit Bergisch Gladbach</name>
      <address>
        <city>Bergisch Gladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Bielefeld, GÃ¼tersloh; Mammographie-Einheit Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit MÃ¼nster-SÃ¼d; Mammographie-Einheit Coesfeld</name>
      <address>
        <city>Coesfeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Duisburg; Mammographie-Einheit Duisburg</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Gelsenkirchen, Kreis Recklinghausen, Bottrop; Mammographie-Einheit Gelsenkirchen</name>
      <address>
        <city>Gelsenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45894</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Minden-LÃ¼bbecke, Herford; Mammographie-Einheit Herford</name>
      <address>
        <city>Herford</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit MÃ¶nchengladbach, Krefeld, Viersen; Mammographie-Einheit Krefeld</name>
      <address>
        <city>Krefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit HÃ¶xter, Paderborn, Soest; Mammographie-Einheit Lippstadt</name>
      <address>
        <city>Lippstadt</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59555</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Referenz-Screeening-Einheit MÃ¼nster-Nord/Warendorf; Mammographie-Einheit MÃ¼nster-Nord</name>
      <address>
        <city>MÃ¼nster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit MÃ¼nster-SÃ¼d; Mammographie-Einheit MÃ¼nster</name>
      <address>
        <city>MÃ¼nster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit HÃ¶xter, Paderborn, Soest; Mammographie-Einheit Paderborn</name>
      <address>
        <city>Paderborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit MÃ¤rkischer Kreis, Hamm, Unna; Mammographie-Einheit Schwerte</name>
      <address>
        <city>Schwerte</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Raum Bergisch Land/Kreis Mettmann; Mammographie-Einheit Solingen-Mitte</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42651</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Raum Bergisch Land/Kreis Mettmann; Mammographie-Einheit Wuppertal-Elberfeld</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://bmjopen.bmj.com/content/8/5/e020475</url>
    <description>BMJ Open</description>
  </link>
  <reference>
    <citation>Weigel S, Gerss J, Hense HW, Krischke M, Sommer A, Czwoydzinski J, Lenzen H, Kerschke L, Spieker K, Dickmaenken S, Baier S, Urban M, Hecht G, Heidinger O, Kieschke J, Heindel W. Digital breast tomosynthesis plus synthesised images versus standard full-field digital mammography in population-based screening (TOSYMA): protocol of a randomised controlled trial. BMJ Open. 2018 May 14;8(5):e020475. doi: 10.1136/bmjopen-2017-020475.</citation>
    <PMID>29764880</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Population-based Screening</keyword>
  <keyword>Digital Breast Tomosynthesis plus synthesized Mammography</keyword>
  <keyword>Reconstructed Mammography</keyword>
  <keyword>Full-Field Digital Mammography (FFDM)</keyword>
  <keyword>Multicentric Randomized Controlled Trial</keyword>
  <keyword>Diagnostic Performance</keyword>
  <keyword>Recall Rate</keyword>
  <keyword>Interval Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

